20 results on '"Annika von Heymann"'
Search Results
2. Compassionate Communication and Advance Care Planning to improve End-of-life Care in Treatment of Haematological Disease ‘ACT’: Study Protocol for a Cluster-randomized trial
- Author
-
Mary Jarden, Christoffer Johansen, Annika von Heymann, Cæcilie Borregaard Myrhøj, and Stine Novrup Clemmensen
- Subjects
Medicine - Abstract
Introduction To support the implementation of advance care planning and serious illness conversations in haematology, a previously developed conversation intervention titled ‘Advance Consultations Concerning your Life and Treatment’ (ACT) was found feasible. This study aims to investigate the effect of ACT on the quality of end-of-life care in patients with haematological malignancy and their informal caregivers.Methods and analysis The study is a nationwide 2-arm cluster randomised trial randomising 40 physician–nurse clusters across seven haematological departments in Denmark to provide standard care or ACT intervention. A total of 400 patients with haematological malignancies and their informal caregivers will be included. The ACT intervention includes an ACT conversation that centres on discussing the patient’s prognosis, worries, hopes and preferences for future treatment. The intervention is supported by clinician training and supervision, preparatory materials for patients and informal caregivers, and system changes including dedicated ACT-conversation timeslots and templates for documentation in medical records.This study includes two primary outcomes: (1) the proportion of patients receiving chemotherapy within the last 30 days of death and (2) patients’ and informal caregivers’ symptoms of anxiety (General Anxiety Disorder-7) at 3 6, 9, 12 and 18 months follow-up. Mixed effects models accounting for clusters will be used.Ethics and dissemination The Declaration of Helsinki and the European GDPR regulations as practised in Denmark are followed through all aspects of the study. Findings will be made available to the participants, patient organisations, funding bodies, healthcare professionals and researchers at national and international conferences and through publication in peer-reviewed international journals.Registration details The study is registered at ClinicalTrials.gov (NCT05444348). The Regional Ethics Committee of the Capital Region of Denmark (record no: 21067634) has decided that approval is not necessary as per Danish legislation. Study approval has been obtained from The Capital Region of Denmark Data Protection Agency (record no: P-2022-93).Trial registration number NCT05444348.
- Published
- 2024
- Full Text
- View/download PDF
3. Examining the efficacy of treatments for arm lymphedema in breast cancer survivors: an overview of systematic reviews with meta-analysesResearch in context
- Author
-
Bolette Skjødt Rafn, Anne Bodilsen, Annika von Heymann, Maja Johannsen Lindberg, Sofia Byllov, Tine Ginnerup Andreasen, Christoffer Johansen, Peer Christiansen, and Robert Zachariae
- Subjects
Complex decongestive physiotherapy ,Exercise ,Laser therapy ,Kinesio taping ,Acupuncture ,Medicine (General) ,R5-920 - Abstract
Summary: Background: Lymphedema affects one in six breast cancer survivors making it a global healthcare challenge. There is considerable debate about the efficacy of different treatments for lymphedema. We aimed to summarize the current evidence for treatments for lymphedema in breast cancer survivors. Methods: In this overview of systematic reviews with meta-analyses (SRMAs), five databases were searched for SRMAs of randomised controlled trials (RCTs) reporting effects of medications, surgery, exercise, laser therapy, acupuncture, kinesio taping, or complex decongestive physiotherapy (CDP) for breast cancer-related lymphedema published from database inception up to March 7, 2023. Data extraction was performed for the SRMAs and RCTs, and SRMAs were appraised with AMSTAR2. Random effects meta-analyses of the RCTs provided estimates of the pooled effects sizes (Hedges’ g) for each treatment modality. This study is registered with PROSPERO, CRD42020184813. Findings: 1569 studies were identified by the search and eighteen SRMAs with 51 RCTs were included, investigating manual lymphatic drainage (MLD), compression pump, exercise, kinesio taping, laser, and acupuncture. Overall, the methodological quality of the SRMAs was low. SRMAs reached different conclusions for all treatment modalities, except for kinesio taping where the two SRMAs found no effect. The analysis of 40 RCTs with 1970 participants revealed a small effect across all interventions compared to any control (g = 0.20, p = 0.047, I2 = 0.79), corresponding to volume reductions of 119.7 ml (95% CI 135–104) and 88.0 ml (95% CI 99–77) in the intervention and control groups, respectively, and a small effect of exercise (g = 0.26, p = 0.022, I2 = 0.44). The between-group differences in volume reduction were small and did not reach statistical significance for any one treatment modality. Interpretation: Based on the available data, there is no evidence of superiority of any one treatment on volume reduction nor any solid research refuting these treatments. Thus, definitive conclusions to inform clinical practice about the efficacy of these treatments cannot be drawn. Due to poor-quality evidence, more research is needed to untangle the efficacy of each treatment component for different stages of lymphedema. Funding: Danish Cancer Society.
- Published
- 2024
- Full Text
- View/download PDF
4. P1177: ROUTINE CLINICAL FOLLOW-UP FOR RELAPSE DETECTION IN PATIENTS WITH LARGE B-CELL LYMPHOMA AFTER FIRST-LINE TREATMENT – DOES NOT MEET THE AIMS. A RETROSPECTIVE DANISH MULTICENTER STUDY
- Author
-
Therese Lassen, Torsten Holm Nielsen, Anne Ortved Gang, Lene Kongsgaard Nielsen, Annika Von Heymann, Christoffer Johansen, and Lars Møller Pedersen
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2023
- Full Text
- View/download PDF
5. Optimising psychological treatment for pain after breast cancer: a factorial design study protocol in Denmark
- Author
-
Anders Bonde Jensen, Christoffer Johansen, Anne Speckens, Annika von Heymann, Yoon Frederiksen, Robert Zachariae, Cecilie Buskbjerg, Mia Skytte O'Toole, and Maja Johannsen
- Subjects
Medicine - Abstract
Introduction One in five breast cancer (BC) survivors are affected by persistent pain years after completing primary treatment. While the efficacy of psychological interventions for BC-related pain has been documented in several meta-analyses, reported effect sizes are generally modest, pointing to a need for optimisation. Guided by the Multiphase Optimization Strategy, the present study aims to optimise psychological treatment for BC-related pain by identifying active treatment components in a full factorial design.Methods and analysis The study uses a 2×3 factorial design, randomising 192 women with BC-related pain (18–75 years) to eight experimental conditions. The eight conditions consist of three contemporary cognitive–behavioural therapy components, namely: (1) mindful attention, (2) decentring, and (3) values and committed action. Each component is delivered in two sessions, and each participant will receive either zero, two, four or six sessions. Participants receiving two or three treatment components will be randomised to receive them in varying order. Assessments will be conducted at baseline (T1), session by session, every day for 6 days following the first session in each treatment component, at post-intervention (T2) and at 12-week follow-up (T3). Primary outcomes are pain intensity (Numerical Rating Scale) and pain interference (Brief Pain Inventory interference subscale) from T1 to T2. Secondary outcomes are pain burden, pain quality, pain frequency, pain catastrophising, psychological distress, well-being and fear of cancer recurrence. Possible mediators include mindful attention, decentring, and pain acceptance and activity engagement. Possible moderators are treatment expectancy, treatment adherence, satisfaction with treatment and therapeutic alliance.Ethics and dissemination Ethical approval for the present study was received from the Central Denmark Region Committee on Health Research Ethics (no: 1-10-72-309-40). Findings will be made available to the study funders, care providers, patient organisations and other researchers at international conferences, and published in international, peer-reviewed journals.Trial registration number ClinicalTrials.gov Registry (NCT05444101).
- Published
- 2023
- Full Text
- View/download PDF
6. Effects on long-term survival of psychosocial group intervention in early-stage breast cancer: follow-up of a randomized controlled trial
- Author
-
Anne Marie Kirkegaard, Susanne Oksbjerg Dalton, Ellen Helle Boesen, Randi V. Karlsen, Henrik Flyger, Christoffer Johansen, and Annika von Heymann
- Subjects
Oncology ,Radiology, Nuclear Medicine and imaging ,Hematology ,General Medicine - Published
- 2023
7. Quality of life and mental health in real-world patients with resected stage III/IV melanoma receiving adjuvant immunotherapy
- Author
-
Sidsel Pedersen, Rikke B. Holmstroem, Annika von Heymann, Laerke K. Tolstrup, Kasper Madsen, Morten Aagaard Petersen, Charlotte A. Haslund, Christina H. Ruhlmann, Henrik Schmidt, Christoffer Johansen, Inge Marie Svane, and Eva Ellebaek
- Subjects
health-related quality of life ,nivolumab ,Oncology ,Radiology, Nuclear Medicine and imaging ,adjuvant therapy ,Hematology ,General Medicine ,immunotherapy ,Melanoma - Abstract
Introduction: Treatment with immune checkpoint inhibitors (ICI) has expanded into the adjuvant setting enhancing the importance of knowledge on the immune-related toxicities and their impact on health-related quality of life (HRQoL). Large phase 3 trials of patients with resected Stage III/IV melanoma found no effect on HRQoL during adjuvant immunotherapy. This study investigates how HRQoL was affected during and after adjuvant immunotherapy in a real-world setting. Methods: Patients with resected melanoma treated with adjuvant nivolumab from 2018 to 2021 in Denmark were identified using the Danish Metastatic Melanoma Database (DAMMED). The study was performed as a nationwide cross-sectional analysis as a questionnaire consisting of six different validated questionnaires on HRQoL, cognitive function, fatigue, depression, fear of recurrence, and decision regret was sent to all patients in March 2021. To evaluate HRQoL during and after adjuvant treatment, patients were divided into groups depending on their treatment status when answering the questionnaire; patients in active treatment for 0–6 months, patients in active treatment for >6 months, patients who ended treatment 0–6 months ago, and patients who ended treatment >6 months ago. Results: A total of 271/412 (66%) patients completed the questionnaire. Patients who ended therapy 0–6 months ago had the lowest HRQoL and had more fatigue. Patients in active treatment for >6 months had lower HRQoL and more fatigue than patients who started treatment 0–6 months ago. Patients ending therapy >6 months ago had higher HRQoL and less fatigue compared to patients who ended therapy 0–6 months ago. Multivariable analysis showed an association between HRQoL and treatment status, comorbidity, civil status, and employment status. Conclusions: Adjuvant nivolumab may affect some aspects of QoL, but the influence seems temporary. Patient characteristics, such as civil status, employment status, and comorbidity were associated with HRQoL.
- Published
- 2023
8. Optimising psychological treatment for pain after breast cancer: a factorial design study protocol in Denmark
- Author
-
Cecilie Buskbjerg, Mia Skytte O'Toole, Robert Zachariae, Anders Bonde Jensen, Yoon Frederiksen, Christoffer Johansen, Annika von Heymann, Anne Speckens, and Maja Johannsen
- Subjects
All institutes and research themes of the Radboud University Medical Center ,Stress-related disorders Donders Center for Medical Neuroscience [Radboudumc 13] ,General Medicine - Abstract
IntroductionOne in five breast cancer (BC) survivors are affected by persistent pain years after completing primary treatment. While the efficacy of psychological interventions for BC-related pain has been documented in several meta-analyses, reported effect sizes are generally modest, pointing to a need for optimisation. Guided by the Multiphase Optimization Strategy, the present study aims to optimise psychological treatment for BC-related pain by identifying active treatment components in a full factorial design.Methods and analysisThe study uses a 2×3 factorial design, randomising 192 women with BC-related pain (18–75 years) to eight experimental conditions. The eight conditions consist of three contemporary cognitive–behavioural therapy components, namely: (1) mindful attention, (2) decentring, and (3) values and committed action. Each component is delivered in two sessions, and each participant will receive either zero, two, four or six sessions. Participants receiving two or three treatment components will be randomised to receive them in varying order. Assessments will be conducted at baseline (T1), session by session, every day for 6 days following the first session in each treatment component, at post-intervention (T2) and at 12-week follow-up (T3). Primary outcomes are pain intensity (Numerical Rating Scale) and pain interference (Brief Pain Inventory interference subscale) from T1 to T2. Secondary outcomes are pain burden, pain quality, pain frequency, pain catastrophising, psychological distress, well-being and fear of cancer recurrence. Possible mediators include mindful attention, decentring, and pain acceptance and activity engagement. Possible moderators are treatment expectancy, treatment adherence, satisfaction with treatment and therapeutic alliance.Ethics and disseminationEthical approval for the present study was received from the Central Denmark Region Committee on Health Research Ethics (no: 1-10-72-309-40). Findings will be made available to the study funders, care providers, patient organisations and other researchers at international conferences, and published in international, peer-reviewed journals.Trial registration numberClinicalTrials.gov Registry (NCT05444101).
- Published
- 2023
9. Effects of home-based specialized palliative care and dyadic psychological intervention on caregiver burden: results from a randomized controlled trial
- Author
-
Annika von Heymann, Emma Finsted, Mai-Britt Guldin, Elisabeth Anne Wreford Andersen, Jesper Dammeyer, Per Sjøgren, Hans von der Maase, Kirstine S. Benthien, Jakob Kjellberg, Christoffer Johansen, and Pernille Bidstrup
- Subjects
palliative care ,psychological intervention ,Oncology ,oncology ,Radiology, Nuclear Medicine and imaging ,Hematology ,General Medicine ,Cancer ,family caregiver - Abstract
Background The Domus study, a randomized controlled trial (RCT), evaluated the effect of home-based specialized palliative care (SPC) reinforced with a psychological intervention for the patient-caregiver dyad on increasing advanced cancer patients’ time spent at home, as opposed to hospitalized, and the number of home deaths. As palliative care extends to include support for patients’ families and may thus assist caregivers and decrease demands on them, in this study we evaluated a secondary outcome, caregiver burden. Material and Methods Patients with incurable cancer and their caregivers were randomized (1:1) to care as usual or home-based SPC. Caregiver burden was assessed using the Zarit Burden Interview (ZBI) at baseline and 2, 4, 8 weeks and 6 months after randomization. Intervention effects were assessed in mixed effects models. Results A total of 258 caregivers were enrolled. Eleven per cent of informal caregivers experienced severe caregiver burden at baseline. Caregiver burden increased significantly over time in both groups (p = 0.0003), but no significant effect of the intervention was seen on overall caregiver burden (p = 0.5046) or burden subscales measuring role and personal strain. Conclusion In line with the majority of previous RCTs, the Domus intervention was not able to significantly reduce caregiver burden. Future interventions should consider targeting only caregivers reporting the greatest caregiver burden.
- Published
- 2023
- Full Text
- View/download PDF
10. Patients in phase 1 cancer trials: psychological distress and understanding of trial information
- Author
-
Morten Mau-Sørensen, Susanne Oksbjerg Dalton, Ulrik Lassen, Anne Katrine Duun-Henriksen, Christoffer Johansen, Beverley Lim Høeg, Pernille Envold Bidstrup, Katrine Toubro Gad, Annika von Heymann, Iben Spanggard, and Kristoffer Staal Rohrberg
- Subjects
medicine.medical_specialty ,Population ,Anxiety ,Psychological Distress ,Neoplasms ,Internal medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,Prospective cohort study ,education ,Adverse effect ,Depression (differential diagnoses) ,education.field_of_study ,Depression ,business.industry ,Cancer ,Hematology ,General Medicine ,medicine.disease ,Clinical trial ,Distress ,Oncology ,medicine.symptom ,business ,Stress, Psychological - Abstract
Background Psychological distress may be present among patients who are considering enrollment in phase 1 cancer trials, as they have advanced cancer and no documented treatment options remain. However, the prevalence of psychological distress has not been previously investigated in larger cohorts. In complex phase 1 cancer trials, it is important to ensure adequate understanding of the study premises, such as the undocumented effects and the risk of adverse events. Materials and methods In a prospective study, patients completed questionnaires at two time points. We investigated psychological distress, measured as stress, anxiety, and depression, among patients at their first visit to the phase 1 unit (N = 229). Further, we investigated the understanding of trial information among patients who were enrolled in a phase 1 cancer trial (N = 57). Results We enrolled 75% of 307 eligible patients. We found a lower mean score of stress in our population compared to population norms, while the mean scores of anxiety and depression were higher. A total of 9% showed moderate to severe symptoms of anxiety and 11% showed moderate to severe symptoms of depression, which indicates higher levels than cancer patients in general. A total of 46 (81% of enrolled patients) completed questionnaires on trial information and consent. The understanding of the information on phase 1 cancer trials in these patients was slightly lower than the level reported for cancer trials in general. Some aspects relating to purpose, benefit, and additional risks were understood by fewer than half of the patients. Conclusion Our results suggest that distress is not as prevalent in the population of patients referred to phase 1 cancer trials as in the general cancer population. Although patients' understanding of trial information was reasonable, some aspects of complex phase 1 cancer trials were not easily understood by enrolled patients.
- Published
- 2021
11. Prevalence of cognitive impairment and its relation to mental health in Danish lymphoma survivors
- Author
-
Gitte M. Knudsen, Kevin Zi Ming Lim, Jonathan Wenstrup, Pernille Envold Bidstrup, Christoffer Johansen, Dea S. Stenbæk, Annika von Heymann, Ian Law, Lena Specht, and Johanna Mariegaard
- Subjects
Pediatrics ,medicine.medical_specialty ,Future studies ,business.industry ,medicine.disease ,Mental health ,Treatment characteristics ,language.human_language ,Lymphoma ,Danish ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,hemic and lymphatic diseases ,030220 oncology & carcinogenesis ,medicine ,language ,Hodgkin lymphoma ,030212 general & internal medicine ,Cognitive impairment ,business ,Diffuse large B-cell lymphoma - Abstract
This study sought to investigate the prevalence of self-reported cognitive impairment and its relation to illness and treatment characteristics and mental health in Hodgkin lymphoma (HL) and diffuse large B cell lymphoma (DLBCL) survivors as cancer-related cognitive impairment has not been extensively studied in lymphoma survivors. One hundred fifteen HL and DLBCL survivors (mean age = 40.3 years, mean months since completed treatment = 29.6) completed questionnaires on executive function and mental health. We examined the prevalence of executive impairment and compared illness and treatment characteristics and mental health across survivors reporting impaired and non-impaired executive functioning using chi-square, Cochran-Armitage, and Mann-Whitney U tests. We found that 39% reported executive impairment. Survivors reporting impaired executive functioning reported worse mental health (ps < .001) than survivors reporting non-impaired executive functioning. A larger proportion of the impaired group had received a high chemo dose compared to the non-impaired group although this result fell short of significance after adjustment for multiple comparisons (p = .017). Self-reported cognitive impairment is prevalent in HL and DLBCL survivors and is associated with worse mental health and possibly high chemo dose. Future studies should investigate objective impairment and the possible dose-response relationship between chemo dose and cognitive impairment in lymphoma survivors.
- Published
- 2020
12. Risk of somatic hospitalization in parents after cancer in a child, a nationwide cohort study
- Author
-
Annika von Heymann, Sierra Alef‐Defoe, Hanin Salem, Elisabeth Anne Wreford Andersen, Susanne Oksbjerg Dalton, Kjeld Schmiegelow, Karin A. W. Wadt, Jeanette Falck Winther, Christoffer Johansen, and Pernille Envold Bidstrup
- Subjects
Adult ,Parents ,parents ,Mothers ,morbidity ,Experimental and Cognitive Psychology ,Cohort Studies ,Hospitalization ,stress ,Psychiatry and Mental health ,Young Adult ,children ,Oncology ,Neoplasms ,oncology ,cancer ,Humans ,Female ,Child - Abstract
Objective: The diagnosis of cancer in a child is a profoundly stressful experience. The impact on parents' somatic health, including lifestyle-related diseases, however, is unresolved. This paper assesses parents' risk of hospitalization with somatic disease after a child's cancer diagnosis. Methods: We conducted a nationwide population- and register-based study with parents of all children under age 20 diagnosed with cancer in Denmark between 1998 and 2013 and parents of cancer-free children, matched (1:10) on child's age and family type. We estimated HR with 95% CI in Cox proportional hazard models for 13 major International Classification of Diseases-10 disease groups, selected stress- and lifestyle-related disease-groups, and investigated moderation by time since diagnosis, parental sex, and cancer type. Results: Among n = 7797 parents of children with cancer compared with n = 74,388 parents of cancer-free children (51% mothers, mean age 42), we found no overall pattern of increased risk for 13 broad disease groups. We found increases in digestive system diseases (HR 1.06, 95% CI 1.01–1.12), genitourinary system diseases (HR 1.08, 95% CI 1.02–1.14), and neoplasms (HR 1.20, 95% CI 1.13–1.27), the latter attributable mostly to increased rates of tobacco-related cancers and mothers' diet-related cancers. Conclusions: This is the first attempt to document the impact of childhood cancer on parents' somatic health. With the exception of increased risk for neoplasms, likely due to shared genetic or lifestyle factors, our findings offer the reassuring message, that the burden of caring for a child with cancer does not in general increase parents' risk for somatic diseases.
- Published
- 2022
13. Late effects–the new focus of follow-up
- Author
-
Christoffer Johansen, Annika von Heymann, Bolette S. Rafn, Signe Borgquist, Peer Christiansen, Peter Christensen, Robert Zachariae, Helle Pappot, and Ulrik Lassen
- Subjects
Oncology ,Disease Progression ,Humans ,Radiology, Nuclear Medicine and imaging ,Survivors ,Hematology ,General Medicine ,Follow-Up Studies - Published
- 2022
14. Oncology to specialised palliative home care systematic transition: the Domus randomised trial
- Author
-
Pernille D. K. Diasso, Jakob Kjellberg, Helle Ussing Timm, Per Sjøgren, Mie Nordly, Christoffer Johansen, Kirstine Skov Benthien, Geana Paula Kurita, Hans von der Maase, and Annika von Heymann
- Subjects
Adult ,Male ,Patient Transfer ,medicine.medical_specialty ,Palliative care ,Psychological intervention ,Medicine (miscellaneous) ,symptoms and symptom management ,Medical Oncology ,Affect (psychology) ,03 medical and health sciences ,0302 clinical medicine ,Neoplasms ,Intervention (counseling) ,Outcome Assessment, Health Care ,medicine ,Humans ,030212 general & internal medicine ,Child ,Trial registration ,Fatigue ,Oncology (nursing) ,business.industry ,Palliative Care ,Symptom burden ,General Medicine ,Middle Aged ,Home Care Services ,Clinical trial ,Medical–Surgical Nursing ,Caregivers ,030220 oncology & carcinogenesis ,Physical therapy ,Female ,Incurable cancer ,business - Abstract
ObjectivesTo assess the effect of a systematic, fast-track transition from oncological treatment to specialised palliative care at home on symptom burden, to explore intervention mechanisms through patient and intervention provider characteristics and to assess long-term survival and place of death.MeasuresThe effect of a systematic, fast-track transition from oncological treatment to specialised palliative care at home on patient symptom burden was studied in the Domus randomised clinical trial. Participants had incurable cancer and limited treatment options. The intervention was provided by specialised palliative home teams (SPT) based in hospice or hospital and was enriched with a psychological intervention for patient and caregiver dyad. Symptom burden was measured with Edmonton Symptom Assessment System (ESAS-r) at baseline, 8 weeks and 6 months follow-up and analysed with mixed models. Survival and place of death was analysed with Kaplan-Meier and Fisher’s exact tests.ResultsThe study included 322 patients. Tiredness was significantly improved for the Domus intervention group at 6 months while the other nine symptom outcomes were not significantly different from the control group. Exploring the efficacy of intervention provider demonstrated significant differences in favour of the hospice SPT on four symptoms and total symptom score. Patients with children responded more favourably to the intervention. The long-term follow-up demonstrated no differences between the intervention and the control groups regarding survival or home deaths.ConclusionsThe Domus intervention may reduce tiredness. Moreover, the intervention provider and having children might play a role concerning intervention efficacy. The intervention did not affect survival or home deaths.Trial registration numberNCT01885637
- Published
- 2020
15. Incidence of New-Onset Type 2 Diabetes After Cancer: A Danish Cohort Study
- Author
-
Lykke Sylow, Mia K. Grand, Annika von Heymann, Frederik Persson, Volkert Siersma, Margit Kriegbaum, Christen Lykkegaard Andersen, and Christoffer Johansen
- Subjects
Advanced and Specialized Nursing ,Endocrinology, Diabetes and Metabolism ,Internal Medicine - Abstract
For patients with cancer, prevalent type 2 diabetes at the date of cancer diagnosis is associated with increased cancerspecific and all-cause mortality (1,2). Yet, despite potential health implications, there is limited knowledge on whether cancer is also a risk factor for type 2 diabetes. Moreover, the impact of new-onset type 2 diabetes after cancer diagnosis on survival among cancer patients is unknown. We investigated the incidence of type 2 diabetes following a cancer diagnosis and evaluated the influence of new-onset type 2 diabetes in patients with cancer onoverall survival.
- Published
- 2022
16. Development of Sarcopenia in Patients With Bladder Cancer: A Systematic Review
- Author
-
Annika von Heymann, Christoffer Johansen, Mikkel Bek Clausen, Helle Pappot, Bolette Skjødt Rafn, Lise Høj Omland, Tobias Tuse Dunk Hansen, and Charlotte Suetta
- Subjects
medicine.medical_specialty ,Sarcopenia ,Muscle mass ,03 medical and health sciences ,0302 clinical medicine ,Quality of life ,Internal medicine ,medicine ,Humans ,In patient ,030212 general & internal medicine ,Retrospective Studies ,Nursing practice ,Bladder cancer ,Oncology (nursing) ,business.industry ,musculoskeletal system ,medicine.disease ,Cancer treatment ,body regions ,Urinary Bladder Neoplasms ,030220 oncology & carcinogenesis ,Time course ,Quality of Life ,business ,human activities - Abstract
Objective Sarcopenia is known to influence cancer-related complications and overall survival. However, the effect of cancer treatment on the development or progression of sarcopenia is relatively unknown. The primary aim of this systematic review was to determine the prevalence and development of sarcopenia among people with bladder cancer. Data Sources A systematic search was performed in PubMed, Web of Science, and EMBASE. Studies with ≥2 assessments of sarcopenia were eligible for inclusion. Five retrospective cohorts were included with a total of 438 participants. The baseline prevalence of sarcopenia across studies varied from 25% to 69% and post-treatment prevalence from 50% to 81%. The average loss of muscle mass was 2.2% to 10% during a time course of 3 to 12 months. Conclusion The prevalence of sarcopenia markedly increased during cancer treatment in patients with bladder cancer. Further research into the effect of different treatment regimens on the development of sarcopenia, and how these changes might affect functional capacity and survival is needed. Implications for Nursing Practice The development of sarcopenia is important to understand because of its negative affect on quality of life, complications, and mortality. Further, understanding how sarcopenia develops during treatment could potentially strengthen nurses’ future care plans for patients with bladder cancer.
- Published
- 2021
17. Prevalence of cognitive impairment and its relation to mental health in Danish lymphoma survivors
- Author
-
Johanna, Mariegaard, Jonathan, Wenstrup, Kevin Zi Ming, Lim, Pernille Envold, Bidstrup, Annika, von Heymann, Christoffer, Johansen, Gitte Moos, Knudsen, Ian, Law, Lena, Specht, and Dea Siggaard, Stenbæk
- Subjects
Adult ,Male ,Executive Function ,Young Adult ,Mental Health ,Cancer Survivors ,Denmark ,Prevalence ,Humans ,Cognitive Dysfunction ,Female ,Middle Aged ,Hodgkin Disease - Abstract
This study sought to investigate the prevalence of self-reported cognitive impairment and its relation to illness and treatment characteristics and mental health in Hodgkin lymphoma (HL) and diffuse large B cell lymphoma (DLBCL) survivors as cancer-related cognitive impairment has not been extensively studied in lymphoma survivors.One hundred fifteen HL and DLBCL survivors (mean age = 40.3 years, mean months since completed treatment = 29.6) completed questionnaires on executive function and mental health. We examined the prevalence of executive impairment and compared illness and treatment characteristics and mental health across survivors reporting impaired and non-impaired executive functioning using chi-square, Cochran-Armitage, and Mann-Whitney U tests.We found that 39% reported executive impairment. Survivors reporting impaired executive functioning reported worse mental health (ps.001) than survivors reporting non-impaired executive functioning. A larger proportion of the impaired group had received a high chemo dose compared to the non-impaired group although this result fell short of significance after adjustment for multiple comparisons (p = .017).Self-reported cognitive impairment is prevalent in HL and DLBCL survivors and is associated with worse mental health and possibly high chemo dose. Future studies should investigate objective impairment and the possible dose-response relationship between chemo dose and cognitive impairment in lymphoma survivors.
- Published
- 2020
18. Dyadic coping in specialized palliative care intervention for patients with advanced cancer and their caregivers:Effects and mediation in a randomized controlled trial
- Author
-
Christoffer Johansen, Jakob Kjellberg, Per Sjøgren, Pernille Envold Bidstrup, Elisabeth Wreford Andersen, Helle Ussing Timm, Annika von Heymann-Horan, Mai-Britt Guldin, Nina Rottmann, and Hans von der Maase
- Subjects
Adult ,Male ,Coping (psychology) ,caregivers ,Palliative care ,psychological adaptation ,Psychological intervention ,Experimental and Cognitive Psychology ,Anxiety ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Psychological adaptation ,Neoplasms ,Adaptation, Psychological ,medicine ,Humans ,cancer ,030212 general & internal medicine ,Aged ,palliative care ,business.industry ,Depression ,Palliative Care ,Middle Aged ,Moderation ,anxiety ,psychotherapy ,Psychiatry and Mental health ,Oncology ,Caregivers ,030220 oncology & carcinogenesis ,Hospice and Palliative Care Nursing ,depression ,oncology ,behavior and behavior mechanisms ,Female ,medicine.symptom ,business ,Clinical psychology ,Dyad - Abstract
OBJECTIVE: Specialized palliative care (SPC) interventions increasingly include patient-caregiver dyads, but their effects on dyadic coping are unknown. We investigated whether an SPC and dyadic psychological intervention increased aspects of dyadic coping in patients with advanced cancer and their caregivers, whether dyad characteristics moderated effects and whether aspects of dyadic coping mediated significant intervention effects on caregivers' anxiety and depression.METHODS: We randomized 258 patients with incurable cancer and their caregivers to care as usual or accelerated transition from oncological treatment to home-based SPC and dyadic psychological support. In secondary outcome analyses, using mixed-effects models, we estimated intervention effects and 95% confidence intervals (CIs) for communication of stress and common coping, and moderation by dyad type and demographics. In path analyses, we investigated whether stress communication and common coping mediated intervention effects on caregivers' symptoms of anxiety and depression. (Clinicaltrials.gov NCT01885637).RESULTS: The intervention significantly increased common coping in patients and caregivers in couples (estimated difference, 0.68; 95% CI, 0.11 to 1.24) and stress communication by partner caregivers (0.97; 0.24 to 1.24). We found some support for different intervention effects for spouses and other dyads, but no evidence of mediation.CONCLUSIONS: Specialized palliative care and dyadic psychological intervention may affect aspects of dyadic coping. Common coping and stress communication did not mediate the previously found significant intervention effects on caregiver anxiety and depression, indicating that other mechanisms may have been central in the intervention.
- Published
- 2019
19. Tele-based Psychological Emotional Support for Informal CARegivers of COVID-19 Patients in Intensive Care (CO-CarES)
- Author
-
Annika von Heymann, Postdoc
- Published
- 2023
20. Stick Together - Pilot Intervention Study
- Author
-
Danish Committee for Health Education, TrygFonden, Denmark, Sygekassernes Helsefond, Danish Cancer Society, University Hospital, Gentofte, Copenhagen, and Annika von Heymann, Post.doc.
- Published
- 2023
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.